Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy

Abstract

Background Antitumor T cell immunotherapy as a novel cancer therapeutic strategy has shown enormous promise. However, the tumor microenvironment (TME) is characterized by the low immunogenicity, hypoxia, and immunosuppressive condition that dramatically limit effective T cell immunotherapy. Thus, an ideal immunotherapy strategy that is capable of reversing the immunosuppressive TME is highly imperative. Results In this article, we reported that Fe-doped and doxorubicin (DOX) loaded HA@Cu2−XS-PEG (PHCN) nanomaterials were rationally designed as targeted Fe-PHCN@DOX nano-nuclear-reactors, which evoked persistent T cell immune response together with anti-PD-L1 nanobodies. It was confirmed that nano-nuclear-reactors displayed strong nanocatalytic effect for effective antitumor effects. Consequently, they maximized the immunogenic cell death (ICD) effect for antigen presentation and then stimulated T cell activation. In addition, Fe-PHCN@DOX could reprogram M2-phenotype tumor-associated macrophages (TAMs) into M1-phenotype TAMs by relieving tumor hypoxia. Meanwhile, blockade of the anti-PD-L1 nanobody promoted T cell activation through targeting the PD-1/PD-L1 immunosuppressive pathway. Notably, in vivo tumor therapy verified that this nano-nuclear-reactor could be used as an excellent immunotherapy nanoplatform for tumor eradication and metastasis prevention with nanobody. Conclusions Our findings demonstrated that nano-nuclear-reactors in combination with nanobody could evoke persistent T cell immune activation, suggesting them potential as a promising immunotherapy option for reversing immunosuppressive immune-cold tumors. Graphical Abstract

Integrated transcriptome, proteome and single‐cell sequencing uncover the prognostic and immunological features of colony‐stimulating factor 3 receptor in pan‐cancer

“…In recent years, increasing studies have shown that tumor immune microenvironment is related to a variety of clinical biological functions in cancers, affecting cancer pathogenesis and the therapeutic response. 28,29 Cells with RUNX1 and CSF3R mutants exhibited the hyperactivation of inflammatory and immune signaling pathways, involving in the development of LAML. 30 CXCL9 may play a protective role in pulmonary fibrosis through abrogating the EMT induced by anti-inflammation factor TGF-β1.…”

Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives

“…[ 130 ] Zhu et al demonstrated the generation of the chemodynamic therapeutic effect through hydroxyl radicals by designing iron‐doped nanomaterials that produced a multimodal synergistic therapy involving DOX chemotherapy and PD‐L1 antibodies. [ 131 ] Nanocarriers doped with iron not only displayed integration of peroxidase activity and drug‐carrying function but also improved targeting compared to using metal complexes directly.…”

Nanocatalytic Anti‐Tumor Immune Regulation

“…[137] Importantly, T cells will intimately interact with APCs, making them suitable for designing nanocatalytic systems for local delivery. [138] Numbers of nanocatalysis-based immunotherapeutic strategies have been proposed aiming to awaken tumor antigen-specific T cells or enhance T cell infiltration to modulate the immunosuppressive tumor microenvironment by APCs activation.…”